title: A baboon syndrome induced by intravenous human immunoglobulins: report of a case and immunological analysis.
abstract: Following the second series of intravenous human immunoglobulins (IVIg; 0.4 g/kg) prescribed to treat a sensorimotor polyneuritis, a 28-year-old woman developed pompholyx that recurred after each of the following monthly treatments with IVIg. During the administration of the 10th series, the patient developed a typical baboon syndrome. Immunohistochemical studies of a skin biopsy revealed an unexpected epidermal expression of P-selectin, usually expressed by endothelial cells. Patch, prick and intradermal tests performed with IVIg on the back, arms and buttocks gave negative results on immediate and delayed readings. IVIg were re-administered, with the informed consent of the patient, and induced a generalized maculopapular rash. This is the first reported case of baboon syndrome induced by IVIg. Although extensive skin testing was performed, all test sites remained negative. We wonder whether IVIg could reproduce immunological mechanisms involved in the 3 types of systemic contact dermatitis (pompholyx, baboon syndrome and maculopapular rash), including the epidermal expression of P-selectin.
authors.affiliation: Dermatology Department, Fournier Hospital, Nancy, France.
authors.forename: A
authors.initials: A
authors.lastname: Barbaud
authors.forename: P
authors.initials: P
authors.lastname: Tréchot
authors.forename: F
authors.initials: F
authors.lastname: Granel
authors.forename: P
authors.initials: P
authors.lastname: Lonchamp
authors.forename: G
authors.initials: G
authors.lastname: Faure
authors.forename: J L
authors.initials: JL
authors.lastname: Schmutz
authors.forename: M C
authors.initials: MC
authors.lastname: Béné
mesh_terms: D000328:Adult; D015922:Complement C1q / Q000032:analysis; D003877:Dermatitis, Contact / Q000209:etiology*; D003875:Drug Eruptions / Q000209:etiology*; D004890:Erythema / Q000139:chemically induced; D005260:Female; D019084:Fluorescent Antibody Technique, Indirect; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects* / Q000627:therapeutic use; D016130:Immunophenotyping; D011115:Polyneuropathies / Q000188:drug therapy; D012867:Skin / Q000737:chemistry / Q000187:drug effects / Q000473:pathology; D012882:Skin Tests; D013577:Syndrome
chemical_list: D016756:Immunoglobulins, Intravenous; D015922:Complement C1q